PDGFRB and pancreatic adenocarcinoma: Weismueller et al. studied the relationship between alterations of the TP53 gene and PDGFRβ (platelet-derived growth receptor beta) in the metastatic capacity of pancreatic adenocarcinoma cells in vitro, which were also related to a worse prognosis in vivo [166].